Surrogate Endpoints for Pulmonary Hypertension Management and Trial Design: Moving in the Right Direction
J Am Coll Cardiol
.
2018 Feb 20;71(7):764-765.
doi: 10.1016/j.jacc.2017.12.029.
Authors
David Jiménez
1
,
Carlos Andrés Quezada
2
,
Pilar Escribano
3
Affiliations
1
Respiratory Department, Hospital Ramón y Cajal and Universidad de Alcalá (IRYCIS), Madrid, Spain. Electronic address: djimenez.hrc@gmail.com.
2
Respiratory Department, Hospital Ramón y Cajal and Universidad de Alcalá (IRYCIS), Madrid, Spain.
3
Cardiology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.
PMID:
29447738
DOI:
10.1016/j.jacc.2017.12.029
No abstract available
Keywords:
morbidity; mortality; pulmonary hypertension; surrogate endpoints.
Publication types
Editorial
Comment
MeSH terms
Biomarkers
Familial Primary Pulmonary Hypertension
Humans
Hypertension*
Hypertension, Pulmonary*
Prognosis
Substances
Biomarkers